Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol. The investigators hypothesize the anticancer activity of low dose OXIRI (LD-OXIRI) regimen comprising of metronomic oxaliplatin (O) and metronomic capecitabine (xeloda; X) in combination with UGT1A1-directed dosing of irinotecan (IRI) to be a tolerable regimen in patients with advanced PDAC and will lead to a favourable response rate. Patients will be prospectively enrolled in two stages - In sta

Trial Details

NCT ID

NCT05929885

Phase

PHASE2

Sponsor

National Cancer Centre, Singapore

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Low Dose OXIRI (LD-OXIRI)

Locations (sample)

• Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

• The patient must meet all of the inclusion criteria to participate in the study.
• Aged above 21
• Histopathological diagnosis of pancreatic cancer
• Advanced disease not amenable to curative resection (locally advanced or metastatic disease)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →